| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA97878
Max Phase: Preclinical
Molecular Formula: C23H32N2O4
Molecular Weight: 400.52
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(=O)N[C@@H](/C=C/C(C)=C/CCCc1ccccc1)[C@H](C)C(=O)N[C@H](C)C(=O)O
Standard InChI: InChI=1S/C23H32N2O4/c1-16(10-8-9-13-20-11-6-5-7-12-20)14-15-21(25-19(4)26)17(2)22(27)24-18(3)23(28)29/h5-7,10-12,14-15,17-18,21H,8-9,13H2,1-4H3,(H,24,27)(H,25,26)(H,28,29)/b15-14+,16-10+/t17-,18+,21-/m0/s1
Standard InChI Key: WXJZLGUUHYFSAT-XGKUTQISSA-N
Associated Targets(Human)
Protein phosphatase 2C beta 71 Activities
Associated Targets(non-human)
Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform 49 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 400.52 | Molecular Weight (Monoisotopic): 400.2362 | AlogP: 3.24 | #Rotatable Bonds: 11 |
| Polar Surface Area: 95.50 | Molecular Species: ACID | HBA: 3 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.87 | CX Basic pKa: | CX LogP: 3.33 | CX LogD: 0.10 |
| Aromatic Rings: 1 | Heavy Atoms: 29 | QED Weighted: 0.39 | Np Likeness Score: 0.76 |
References
| 1. Gulledge BM, Aggen JB, Eng H, Sweimeh K, Chamberlin AR.. (2003) Microcystin analogues comprised only of Adda and a single additional amino acid retain moderate activity as PP1/PP2A inhibitors., 13 (17): [PMID:14611855] [10.1016/s0960-894x(03)00588-2] |
Source
Source(1):